05:00 PM EDT, 07/02/2025 (MT Newswires) -- 4D Molecular Therapeutics ( FDMT ) said late Wednesday that it is accelerating its Phase 3 program for the 4D-150 gene therapy for wet age-related macular degeneration, citing stronger-than-expected enrollment and site activation in its North American trial.

The company cut 25% of its workforce, mainly in early-stage research and development and support roles, to save $15 million as costs rise due to the accelerated clinical trial timelines and biologics license application preparation.

Strong initial enrollment in the North American phase 3 trial prompted the company to move up its topline 52-week data readout to H1 2027, six months earlier than expected. The company said it still expects to maintain more than six months of cash runway beyond the readout.

Cash, cash equivalents, and marketable securities totaled $458 million as of March 31, which the company expects will fund expenses through the trials, BLA submission, continued development of its diabetic macular edema program, and 4D-710 for cystic fibrosis.